MIR584

Summary

MIR584 (microRNA 584, HGNC:32840) is a microRNA gene on chromosome 5q32.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693169 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32840
Approved symbol	MIR584
Name	microRNA 584
Location	5q32
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-584
Ensembl gene	ENSG00000207714
Ensembl biotype	miRNA
Entrez	693169
RNAcentral	URS000066A55E — miRNA, 97 nt, 10 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384981

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384981 — 1 exons

Exon	Start	End
ENSE00001499988	149062313	149062409

Expression profiles

Bgee: expression breadth broad, 43 present calls, max score 78.60.

Top tissues by expression

43 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	78.60	gold quality
vermiform appendix	UBERON:0001154	76.95	gold quality
monocyte	CL:0000576	76.00	gold quality
islet of Langerhans	UBERON:0000006	75.75	gold quality
muscle layer of sigmoid colon	UBERON:0035805	75.01	gold quality
gastrocnemius	UBERON:0001388	74.65	gold quality
body of stomach	UBERON:0001161	73.17	gold quality
placenta	UBERON:0001987	73.14	gold quality
stomach	UBERON:0000945	72.50	gold quality
heart	UBERON:0000948	71.85	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	71.73	gold quality
lung	UBERON:0002048	71.63	gold quality
putamen	UBERON:0001874	70.32	gold quality
Brodmann (1909) area 9	UBERON:0013540	70.04	gold quality
transverse colon	UBERON:0001157	69.84	gold quality
colon	UBERON:0001155	69.54	gold quality
myometrium	UBERON:0001296	69.06	gold quality
heart left ventricle	UBERON:0002084	69.03	gold quality
esophagus mucosa	UBERON:0002469	68.85	gold quality
omental fat pad	UBERON:0010414	68.61	gold quality
right atrium auricular region	UBERON:0006631	67.84	gold quality
tibial artery	UBERON:0007610	67.83	gold quality
popliteal artery	UBERON:0002250	66.93	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	66.65	gold quality
fundus of stomach	UBERON:0001160	66.11	gold quality
corpus callosum	UBERON:0002336	65.70	gold quality
Ammon’s horn	UBERON:0001954	65.57	gold quality
subcutaneous adipose tissue	UBERON:0002190	65.12	gold quality
urinary bladder	UBERON:0001255	65.00	gold quality
lower esophagus muscularis layer	UBERON:0035833	64.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.33

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 36)

• miR-584 contributes to the post-transcriptional expression of lactoferrin receptor during the perinatal period. (PMID:19665576)
• miR-584 is a new tumour suppressor miR in ccRCC and inhibits cell motility through downregulation of ROCK-1 (PMID:21119662)
• miRNA-584 and miRNA-1290, upregulated by the CagA protein of H, pylori, interfere with cell differentiation and are implicated in metaplasia and tissue remodeling. (PMID:22536353)
• a novel signaling route whereby TGF-beta silences the expression of miR-584, resulting in enhanced PHACTR1 expression, and further leading to actin rearrangement and breast cancer cell migration. (PMID:23479725)
• miR-31 and miR-584 bind strongly to the hAGT 3’-UTR containing 11525C allele compared with 11525A allele. (PMID:23943853)
• These findings indicate that miR-584 suppresses glioma cell growth by negatively regulating the expression of PTTG1IP, suggesting that miR-584 has a tumor suppressive role in human glioma pathogenesis. (PMID:25674221)
• Upregulation of microRNA335 and microRNA584 contributes to the pathogenesis of severe preeclampsia through downregulation of endothelial nitric oxide synthase (PMID:26133786)
• These results indicate that miR-584 could inhibit the expression of ROCK1, and ROCK1 knockdown would further affect the migration ability of K1 cells. (PMID:26405762)
• MiR-26a and mir-584 inhibit the binding of hnRNP A1-CDK6 mRNA and induce colorectal cancer cell apoptosis. (PMID:26494299)
• Low miR-584-3p expression is associated with glioma. (PMID:26715733)
• The results suggest that a disease-associated SNP located within the 3’UTR of KLRG1 directly interferes with miR-584-5p binding, allowing for KLRG1 mRNA differential accumulation, which in turn may contribute to pathogenesis of pemphigus. (PMID:27424220)
• Data show that TUSC2 is a direct target of miR-584, which is transcriptionally regulated by TWIST1. (PMID:27661106)
• Our results demonstrate a tumor suppressor function for miR-584-3p in glioma, where it inhibits the vasculogenic mimicry of tumor cells by antagonizing hypoxia-induced ROCK1-dependent stress fiber formation. (PMID:27881000)
• Results show that MiR-584-5p is down-regulated in human gastric cancer (GC) tissues and cells, and indicated that miR-584-5p downregulation is vital for the development and progression of GC. (PMID:28431583)
• Two miRNAs, miR-584-5p and miR-1249, that matched with the PB2 binding sequence, dramatically down-regulated PB2 expression, and inhibited replication of H5N1 and H1N1 influenza A virus strains in A549 cells. (PMID:28609011)
• These data demonstrate that miR-584-3p directly targets the MMP-14 promoter to repress YY1-facilitated MMP-14 expression and inhibits the progression of gastric cancer. (PMID:28827574)
• These findings identify a previously undefined role for miR-584-5p/HDAC1/eIF4E3 in regulating DNA repair, microtubule dynamics, and stemness in medulloblastoma and set the stage for a new way to treat medulloblastoma using miR-584-5p. (PMID:30382096)
• This study identifies FLI1 exonic circular RNAs as a new oncogenic driver that promotes tumor metastasis through the miR584-ROCK1 pathway. Importantly, serum exosomal FECR1 may serve as a promising biomarker to track disease progression of small cell lung cancer (SCLC) (PMID:30429198)
• Low miR584 expression is associated with proliferation and invasion of pancreatic cancer. (PMID:30431107)
• Long noncoding RNA LOC101927746 interacts with miR-584-3p which targets SSRP1. LOC101927746/miR-584-3p/SSRP1 pathway modulates colorectal cancer progression. (PMID:30616889)
• miR5845p also inhibited the expression of MMP4 and Slug, which are involved in tumor invasion and metastasis. Taken together, these results indicated that the miR5845p/MMP14 axis may serve as an anticancer target in the treatment of nonsmallcell lung cancer patients. (PMID:30628644)
• In vitro functional assays showed miR-584-5p depletion decreased HCC cell proliferation, cell migration, and cell invasion. Moreover, miR-584-5p functions by directly targeting KCNE2, and it in turn, mediates the effects of miR-584-5p on HCC cell behaviors. (PMID:31044566)
• Hsa-miR-584-5p as a novel candidate biomarker in Turkish men with severe coronary artery disease. (PMID:31863331)
• MiRNA-584 suppresses the progression of ovarian cancer by negatively regulating LPIN1. (PMID:32096176)
• Knockdown of microRNA-584 promotes dental pulp stem cells proliferation by targeting TAZ. (PMID:32208890)
• MiRNA-584 suppresses the progression of NK/T-cell lymphoma by targeting FOXO1. (PMID:32373978)
• Circular RNA ABCB10 promotes non-small cell lung cancer progression by increasing E2F5 expression through sponging miR-584-5p. (PMID:32420810)
• Hepatocellular carcinoma cell-derived extracellular vesicles encapsulated microRNA-584-5p facilitates angiogenesis through PCK1-mediated nuclear factor E2-related factor 2 signaling pathway. (PMID:32522621)
• Fluctuating expression of miR-584 in primary and high-grade gastric cancer. (PMID:32615958)
• circRNA 001306 enhances hepatocellular carcinoma growth by up-regulating CDK16 expression via sponging miR-584-5p. (PMID:33135290)
• Downregulated long intergenic non-coding RNA 00,174 represses malignant biological behaviors of lung cancer cells by regulating microRNA-584-3p/ribosomal protein S24 axis. (PMID:35451652)
• Long Non-Coding RNA DUXAP8 Acts as an Oncogene in Sinonasal Squamous Cell Carcinoma Through miR-584-5p/FNDC3B Pathway. (PMID:35695194)
• Regulations of LINC0196/miR-584-5p/miR-34a-5p/TRIM59 on Progression of Pediatric Neuroblastoma. (PMID:36227666)
• Circ_0079530 stimulates THBS2 to promote the malignant progression of non-small cell lung cancer by sponging miR-584-5p. (PMID:36382967)
• The neuropathological mechanism of EV-A71 infection attributes to inflammatory pryoptosis and viral replication via activating the hsa_circ_0045431/ hsa_miR_584/NLRP3 regulatory axis. (PMID:37579846)
• Biomarker of Pulmonary Inflammatory Response in LUAD: miR-584-5p Targets RAB23 to Suppress Inflammation Induced by LPS in A549 Cells. (PMID:38093594)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.